Cell Signaling Technology

Product Pathways - MAPK Signaling

Phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Mouse mAb #9106

Applications Reactivity MW (kDa) Source Isotype
W IP IF-IC F H M R Mk Mi Hm B Dr Z 42, 44 Mouse IgG1kappa

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IF-IC=Immunofluorescence (Immunocytochemistry)  F=Flow Cytometry
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey  Mi=Mink  Hm=Hamster  B=Bovine  Dr=Drosophila  Z=Zebra Fish
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

Phospho-p44/42 MAP Kinase (Thr202/Tyr204) (E10) Mouse mAb detects endogenous levels of p44 and p42 MAP Kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Tyr204. This antibody does not cross-react with the corresponding phosphorylated residues of either SAPK/JNK or p38 MAP kinase. This antibody may cross-react with an unknown cytoskeletal protein in some cell lines as visualized by immunofluorescence.

Source / Purification

Monoclonal antibody (isotype: mouse IgG1) is produced by immunizing mice with a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Thr202/Tyr204 of human p44 MAP kinase.

Western Blotting

Western Blotting

Specificity and sensitivity of the Phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Mouse mAb: This antibody reacts specifically with as little as 50 pg of phosphorylated MAP kinase and does not cross-react with up to 4 µg of nonphosphorylated MAP kinase by Western blotting.

Western Blotting

Western Blotting

Western blot analysis of extracts from FGF treated SK-N-MC cells, using Phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Mouse mAb (upper) or control p44/42 MAPK Antibody #9102 (lower).

Flow Cytometry

Flow Cytometry

Flow cytometric analysis of Jurkat cells, untreated (red) or PMA-treated (blue) ; and untreated (green) or PMA-treated (purple) following 90-minute CIP treatment, using Phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Mouse mAb.


IF-IC

IF-IC

Confocal immunofluorescent images of Phospho-p44/42 MAPK (Thr202/Tyr204) (E10) Mouse mAb (green) and Phospho-Akt (Ser473) (193H12) Rabbit mAb #4058 (red) in C6 rat glioma cells treated with LPA as indicated. LPA induces cytoplasmic and nuclear phospho-p44/42 MAPK signal as well as cytoplasmic and membrane phospho-Akt signal. Addition of MEK inhibitor U0126 #9903 or PI3K inhibitor LY294002 #9901 completely blocks activation of phospho-p44/42 MAPK or phospho-Akt, respectively. Blue pseudocolor = DRAQ5™ (fluorescent DNA dye).

Background

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (ERK1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3) and is an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK), and a MAP kinase. While multiple ERK1/2 MAP3Ks have been identified, including the Raf family, Mos, and Tpl2/Cot, MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate ERK1/p44 and ERK2/p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of ERK1/2 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). ERK1/2 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors such as U0126 and PD98059.

  1. Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
  2. Baccarini, M. (2005) FEBS Lett 579, 3271-7.
  3. Meloche, S. and Pouyssegur, J. (2007) Oncogene 26, 3227-39.
  4. Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.
  5. Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.
  6. Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.
  7. Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
  8. Marais, R. et al. (1993) Cell 73, 381-93.
  9. Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
  10. Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes